AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the P...
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade ...
Amgen: I Prefer To Chase Value And Dividends
Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a robu...
Amgen: The Giant With An Impressive Pipeline
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024, f...
Final Trades: Shell, 2-YR T-Note and Amgen
The Investment Committee give you their top stocks to watch for the second half.
Amgen (AMGN) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
2 Biotech Stocks to Buy Hand Over Fist in April
Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.
Building A $1.4 Million Retirement Fund: 4 Stocks Yielding Up To 6% To Get The Job Done
As the retirement crisis looms, urgent action is key. The financial industry's failure to address rising retirement costs exacerbates the situation. Investing in dividend-growth stocks emerges as a...
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
Amgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and n...
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.
Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ca...
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
Related Companies